Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Rebif (Clone 484-39) in RRMS
NCT00367484Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- May 2004
- Primary completion
- Jan 2006
- Modality
- Cytokines & Interferons
01
Overview
A Phase 4 trial of interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS), sponsored by Merck KGaA. Started May 2004; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00367484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367484.